• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 Management

COVID-19 Real-World Vaccine Effectiveness in Health Care Personnel

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Pilishvili et al. (NEJM, 2021) evaluated COVID-19 vaccine effectiveness in health care personnel according to vaccine product

METHODS:

  • Test-negative case-control study
  • Participants
    • Health care personnel across 25 states who had been tested for SARS-CoV-2
    • Enrolled from December 2020 (2 weeks following introduction of COVID-19 vaccine) through May 2021
  • Exposures
    • Vaccine product
      • Moderna
      • Pfizer
    • Vaccine status
      • Partial vaccination
        • 14 days after receipt of the first dose through 6 days after receipt of the second dose
      • Complete vaccination
        • ≥7 days after receipt of the second dose
  • Study design
    • Cases and controls were matched according to week of the test date and site
      • Cases were determined by PCR or antigen-based tests and at least one COVID-19 symptom
    • Vaccine effectiveness was adjusted for age, race and ethnic group, underlying conditions, and exposures to persons with COVID-19
  • Primary outcome
    • Vaccine effectiveness

RESULTS:

  • Cases: 1482 participants | Controls: 3449 participants
  • Vaccine effectiveness for partial vaccination
    • Pfizer: 77.6% (95% CI, 70.9 to 82.7)
    • Moderna: 88.9% (95% CI, 78.7 to 94.2)
  • Vaccine effectiveness for complete vaccination
    • Pfizer: 88.8% (95% CI, 84.6 to 91.8)
    • Moderna: 96.3% (95% CI, 91.3 to 98.4)
  • Vaccine effectiveness was similar in subgroups defined according to a
    • Age (<50 years or ≥50 years)
    • Race and ethnic group
    • Presence of underlying conditions
    • Level of patient contact
  • Evidence of waning vaccine effect assessed in 2 week intervals after receipt of second dose
    • Lower during weeks 9 through 14 than during weeks 3 through 8 after receipt of the second dose, but large overlapping CIs

CONCLUSION:

  • During the study period, vaccine effectiveness in health care personnel for both the Pfizer and Moderna COVID-19 vaccines was high (~89% for Pfizer and ~96% for Moderna)
  • Vaccine effectiveness was similarly high for adults of different ages, races/ethnicities, and with underlying conditions
  • The authors state

In this population of health care personnel, vaccine effectiveness was similar among persons with underlying medical conditions or other risk factors for severe Covid-19, including pregnancy; in different subgroups of health care personnel defined according to job category; and in racial and ethnic groups that have been disproportionately affected by the pandemic

The long-term duration of protection and the effectiveness of these vaccines against emerging variants is unknown and should be monitored to indicate whether changes to vaccine composition or vaccine policy are needed

Learn More – Primary Sources:

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

COVID-19 mRNA Vaccine Effectiveness in the Real World Including in Those Partially Immunized
AstraZeneca and Pfizer Side Effects and Efficacy: Real World Data from the UK
Vaccine Effectiveness Against Hospitalization in the U.S. for Moderna, Pfizer and J&J

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site